Jack C Yalowich, PhD

Jack Yalowich


College of Pharmacy


College of Pharmacy

Academic Title


Research Program

Translational Therapeutics

Research Interest

DNA Damage ● Leukemia ● Carcinoma, Ehrlich Tumor ● Leukemia, Erythroblastic, Acute ● Leukemia L1210 ● Oxidative stress ● DNA Breaks, Double-Stranded ● Leukemia, Myeloid ● Breast Cancer ● Cancer

Jack Yalowich, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where his research focuses on therapeutic treatment and prevention of cancers.

In particular, he is exploring how to improve ability of the clinically effective anticancer agent etoposide (VP-16) in cancer treatment as well as how to prevent benzene leukemogenesis.

One of his recent studies revealed that the molecule, tripartite motif protein 72 (TRIM72) could be a therapeutic target for patients with injured lungs.

Dr. Yalowich has co-authored many articles in well-respected publications, including Journal of Pharmacology and Experimental Therapeutics, Bioorganic & Medicinal Chemistry, Biochemical Pharmacology and Phytochemistry.

Office Location

532 Parks Hall

500 W 12th Ave, Columbus, OH 43210




Back to Researcher Search

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Search for Clinical Trials

Find a Scientific Publication